Previous Page  7 / 22 Next Page
Information
Show Menu
Previous Page 7 / 22 Next Page
Page Background

conferenceseries LLC Ltd

Notes:

Page 38

Clinical Pharmacology & Biopharmaceutics | ISSN : 2167-065X

Volume 7

September 18-19, 2018 | Amsterdam, Netherlands

6

th

European Biopharma Congress

Euro Biopharma 2018

Physicochemical characterization of the starch fromEthiopian potato

(Plectranthus edulis)

: a potential pharmaceutical

excipient

Anteneh Assefa

1

, Anteneh Belete

2

and

Tsige Gebre-Mariam

2

1

Wachemo University, Ethiopia

2

Addis Ababa University, Ethiopia

S

tarch from the tubers of Ethiopian potato

(Plectranthus edulis) (Fam. Lamiaceae)

has been isolated and examined for its chemical

composition, amylose content and physicochemical properties. The yield of starch was about 80.4% on dry weight basis. The proximate

composition of the starch on dry weight basis was found to be 0.14% ash, 0.21% lipid, 0.43% protein, and 99.22% starch. The amylose

content was 30.6%. Its true density and moisture content values were 1.47 g/ml and 11.2%, respectively. Scanning electron microscopy

(SEM) of the starch granules showed characteristic morphology that was by large oblong (elliptical) with some oval-shaped granules. The

starch has normal granule size distribution with a mean particle size of 36.20 µm. The DSC thermograms of P.

edulis

starch obtained from

starch-water mixtures (1:1), exhibited higher T

o

(69.2°C), T

p

(74.3°C) and T

e

(83.3°C) values than those of potato starch. X-ray diffraction

pattern of the starch was typical B-type with a distinctive maximum peak at 17.5o2θ. The starch possesses higher swelling power and

moisture sorption pattern, but lower solubility values than those of potato starch at all temperatures studied. Considering the high yield

value and some similar physico-chemical properties to those of potato starch, P.

edulis

(Ethiopian potato) can be explored as an alternative

source of starch for various applications.

ante2011@gmail.com

Clin Pharmacol Biopharm 2018, Volume:7

DOI: 10.4172/2167-065X-C1-029